Ernexa Therapeutics Inc.
ERNA Nasdaq
SEC CIK 748592
Follow Ernexa Therapeutics
Weekly email: filings, results
Net income
−$2.9M
−137.2% vs same quarter last year
EPS, diluted
−$1.89
Operating cash flow
−$3.2M
−149.2% vs same quarter last year
Operating income
−$3M
−50% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | - | −$14.1M |
| FY24 | $582K | −$44.5M |
| FY23 | $68K | −$21.7M |
| FY22 | $0 | −$24.6M |
| FY21 | - | −$122.5M |
| FY20 | $5.8M | −$7.3M |
| FY19 | $19.8M | −$2M |
| FY18 | $23.3M | −$259K |
| FY17 | $21.3M | −$1.1M |
| FY16 | $22.3M | −$2.9M |
| FY15 | $24.5M | −$7.2M |
| FY14 | $26M | −$5M |
| FY13 | $23.7M | −$1.1M |
| FY12 | $24.1M | −$995K |
| FY11 | $23.9M | −$3.4M |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | - | - |
| FY24 | −2693.1% | −7652.7% |
| FY23 | −31080.9% | −31864.7% |
| FY22 | - | - |
| FY21 | - | - |
| FY20 | −125% | −125.7% |
| FY19 | −8.9% | −10.3% |
| FY18 | 0.9% | −1.1% |
| FY17 | −6.6% | −5.1% |
| FY16 | −10.2% | −13.1% |
| FY15 | −28.1% | −29.5% |
| FY14 | −18.2% | −19.3% |
| FY13 | −4.7% | −4.4% |
| FY12 | −4.4% | −4.1% |
| FY11 | −13.7% | −14.3% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$7.1M |
| FY24 | −$16.2M |
| FY23 | −$20.4M |
| FY22 | −$21.3M |
| FY21 | −$23.6M |
| FY20 | −$8.1M |
| FY19 | $2.6M |
| FY18 | $717K |
| FY17 | −$179K |
| FY16 | −$404K |
| FY15 | −$5.2M |
| FY14 | −$7.2M |
| FY13 | $632K |
| FY12 | $930K |
| FY11 | −$1M |
- Ernexa Therapeutics
- Healthcare median
Show the numbers
| Year | Ernexa Therapeutics | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | −7652.7% | −47% |
| FY23 | −31864.7% | −58% |
| FY22 | - | −80.4% |
| FY21 | - | −71.9% |
| FY20 | −125.7% | −62.2% |
| FY19 | −10.3% | −46.3% |
| FY18 | −1.1% | −49.6% |
| FY17 | −5.1% | −45.9% |
| FY16 | −13.1% | −36% |
| FY15 | −29.5% | −38.4% |
| FY14 | −19.3% | −35.5% |
| FY13 | −4.4% | −37.1% |
| FY12 | −4.1% | −29.1% |
| FY11 | −14.3% | −27.9% |